Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $12.6 million.

  • Myriad Genetics' Depreciation & Amortization (CF) fell 19.23% to $12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.9 million, marking a year-over-year decrease of 9.11%. This contributed to the annual value of $61.2 million for FY2024, which is 1.13% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Depreciation & Amortization (CF) is $12.6 million, which was down 10.64% from $14.1 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Depreciation & Amortization (CF) peaked at $19.4 million during Q1 2023, and registered a low of $12.6 million during Q3 2025.
  • In the last 3 years, Myriad Genetics' Depreciation & Amortization (CF) had a median value of $14.8 million in 2024 and averaged $14.9 million.
  • In the last 5 years, Myriad Genetics' Depreciation & Amortization (CF) crashed by 62.85% in 2021 and then spiked by 49.23% in 2023.
  • Quarterly analysis of 5 years shows Myriad Genetics' Depreciation & Amortization (CF) stood at $13.3 million in 2021, then increased by 3.01% to $13.7 million in 2022, then rose by 10.22% to $15.1 million in 2023, then decreased by 1.99% to $14.8 million in 2024, then fell by 19.23% to $12.6 million in 2025.
  • Its last three reported values are $12.6 million in Q3 2025, $14.1 million for Q2 2025, and $14.4 million during Q1 2025.